In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $8.15.
According to TipRanks, Gon Ha is a 3-star analyst with an average return of 1.3% and a 36.61% success rate. Gon Ha covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Amicus, and Ultragenyx Pharmaceutical.
Currently, the analyst consensus on Fulcrum Therapeutics is a Moderate Buy with an average price target of $8.50.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $13.22 and a one-year low of $2.25. Currently, Fulcrum Therapeutics has an average volume of 614.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulcrum Therapeutics (FULC) Company Description:
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More on FULC:
